Hillhouse Investment Group

Huashen Zhiyao is a biotechnology company that accelerates novel drug discovery for unmet medical needs. Huashen Zhiyao develops an AI drug development platform and antibody engineering experiment platform to provide researchers with intelligent systems for microscopic molecular calculation, simulation, and design, committing to improving the speed and efficiency of new drug development.

The main business of "Qingyun New Materials" is to develop, produce and sell flash-spun metamaterial Kunlun® Hypak® , which is a high-strength, waterproof and breathable special fiber material that is arranged in the form of non-woven fabrics.

Shenzhen Dynanonic Co., Ltd. is a Chinese company founded in January 2007, specializing in the research, development, production, and sale of nanomaterials. Headquartered in Nanshan District, Shenzhen, the company focuses on nano-scale materials, including nano-lithium iron phosphate, carbon nanotube conductive liquids, carbon nanotubes, and bag graphene. Dynanonic has established research and production facilities in multiple locations across China, including Foshan City in Guangdong Province, Feicheng City in Shandong Province, and Pingshan District in Shenzhen. Recognized as a national high-tech enterprise, Dynanonic is committed to advancing the industrial applications of its nanomaterials.

Starna Therapeutics offers development of innovative drugs with RNA as the core, and has an industry-leading RNA and organ-selective delivery technology platform with independent intellectual property rights; the company has established a rich R&D pipeline , covering infectious disease vaccines, tumor immunity and other fields.

Enkris Semiconductors specializes in the development of high-quality gallium nitride (GaN) epitaxial wafers tailored for power electronics and micro-display applications. The company offers a range of material solutions, including GaN-on-Si, GaN-on-SiC, GaN-on-Sapphire, and GaN-on-GaN, which are designed to support the next generation of RF devices and micro-LED technology. By utilizing CMOS-compatible technology, Enkris Semiconductors aims to produce reliable and cost-effective GaN materials, allowing businesses in power electronics and micro-display sectors to enhance their product performance and efficiency. Through its focus on innovation and quality, the company is positioned to meet the growing demands of these advanced technological fields.

SceneRay Corporation, Limited is a medical device company based in Suzhou, China, specializing in the design, development, and distribution of neuromodulation devices. The company offers a range of products, including a deep brain stimulation system that features an implantable neuro-stimulator, patient controller, and various accessories. Additionally, SceneRay develops spinal cord stimulation and sacral nerve stimulation systems. The team at SceneRay comprises experts with extensive experience in neuromodulation device development, manufacturing, and marketing, and the company holds numerous patents in this field. Committed to advancing neuromodulation solutions, SceneRay aims to provide patients with high-quality and effective treatments.

Developer of synthetic biotechnology intended to facilitate microbial manufacturing and material innovation. The company focuses on the research and development of synthetic biotechnology and applies synthetic biology to create new bio-manufacturing products and to optimize cells from energy to medicines among other applications, enabling clients to assemble products by bio-engineering cell materials.

Guoyi Quantum is a company that uses quantum precision measurement as its core technology to provide enterprises, governments, and research institutions around the world with core key devices represented by enhanced quantum sensors, scientific instruments and equipment for analysis and testing, and enable industry applications. Products and services such as core technology solutions. The company faces the fields of advanced materials, semiconductors, quantum science, life technology, medicine and clinical research, and is committed to helping customers promote the development of technology more efficiently and explore the future of mankind.

NASN Automotive Electronics is committed to providing advanced and complete chassis electronic control products, ADAS and autonomous driving related core technologies for the Chinese automotive market. The main products include NBooster intelligent brake system, brushless electric steering EPS controller and wire control system. It is a scientific and technological innovation enterprise integrating R&D, production and sales.

DPTechnology, founded in 2018 and based in Beijing, China, specializes in micro-scale industrial design through advanced molecular simulation technology. The company has developed a platform that integrates artificial intelligence with molecular simulation algorithms, aiming to enhance industrial and medical research. By providing users with innovative scientific tools, DPTechnology promotes efficiency and creativity in exploring complex research challenges, thereby establishing a new paradigm in both industrial research and clinical applications.

Deyun Kangrui is a bio-medical high-tech enterprise that integrates R&D and the production of full-chain single-cell multi-omics technology.

Developer of artificial meat. The company develops artificial meat and cultured alternative protein products at the cellular level, committing to creating a new solution for future food supply.

Huashen Zhiyao is a biotechnology company that accelerates novel drug discovery for unmet medical needs. Huashen Zhiyao develops an AI drug development platform and antibody engineering experiment platform to provide researchers with intelligent systems for microscopic molecular calculation, simulation, and design, committing to improving the speed and efficiency of new drug development.

Etern is developing small molecule innovative drugs for oncology therapies.

SolarPlant Technology is a Chinese perovskite photovoltaic cell company. As a brand-new semiconductor material, perovskite has broad application prospects in photovoltaic, detection, display, lighting and other fields. SolarPlant Technology’s perovskite/crystalline silicon stacked photovoltaic technology can be deeply integrated with crystalline silicon technology, breaking through the photovoltaic conversion efficiency limit of traditional single-junction solar cells, and further reducing the cost of photovoltaic power generation.

Pulse Medical Technology develops innovative technology for the diagnosis and optimal treatment of pan-vascular diseases.

Chengdu Qitan Technology Co., Ltd. specializes in the development and manufacture of advanced gene sequencing instruments utilizing nanopore technology. Founded in 2016 and based in Chengdu, China, the company offers a fourth generation gene sequencer that enables single-molecule sequencing with long read lengths and real-time output. This innovative technology is designed to serve various sectors, including biopharmaceuticals, healthcare, and agriculture, facilitating applications such as immunophenotyping, pathogen detection, analysis of intestinal flora, and tumor genome detection. Qitan Tech's solutions are notable for their cost-effectiveness and simplicity, as they do not require complicated library preparation, thus enhancing the accessibility of gene sequencing for cutting-edge biological research and clinical diagnostics.

Nanjing Bioheng Biotech Co., Ltd., established in 2017 and based in Nanjing, China, is a clinical biopharmaceutical and biotechnology company that focuses on developing innovative immunotherapies and next-generation gene therapies for cancer and other diseases. The company offers advanced gene editing techniques and CAR-T therapies, and has created a robust production platform for plasmid, virus, and cell manufacturing. Bioheng has developed a GMP-grade clinical translational center and is recognized for its expertise in cell engineering and clinical applications. With a commitment to creating safer and more affordable cell therapy drugs, Bioheng aims to enhance patient access to effective treatments. The company has secured significant funding to further its research and development efforts, leveraging its extensive patent portfolio and industry experience to drive advancements in immunotherapy.

Cryofocus Biotech is a Shanghai-based cryoablation device manufacturer, focusing on the application of cryogenic technology in the field of cardiovascular interventional therapy.

Beijing Targeting One Technology Co., Ltd. engages in the development and production of biomedical instruments, consumables, and in vitro diagnostic reagents for use in the fields of precision medicine, health management, and life science research. The company offers drop maker sample preparation apparatus, biochip readers, digital PCR supplies, ddPCR universal amplification reagents, micro-droplet generation and detection oils, genetic testing kits, and nucleic acid extraction reagents. Its digital PCR products have applications in the areas of transplant rejection monitoring, targeted sequencing, tumor liquid biopsy, and non-invasive prenatal screening. Beijing Targeting One Technology Co., Ltd. was founded in 2015 and is based in Beijing, China.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Hemu (China) Biological Engineering is a Chinese blood vessel intervention medical equipment firm.

MicroPort Medbot develops and provides intelligent surgical solutions and clinical needs of minimal invasive surgery, to explore the technology of smart robots, intelligent control, information sensing, and more. MicroPort Medbot develops a product portfolio of 3D electronic laparoscopy, laparoscopic surgical robot, and orthopedic surgical robot, providing intelligent surgical solutions. MicroPort Medbot is headquartered in Shanghai, China.

Yunjing (Narwal) Intelligence Technology (Dongguan) Co., Ltd. designs, develops, and produces intelligent cleaning robots. The company offers Narwal T10, a self-cleaning robot cleaner for automated mop cleaning, floor cleaning, and smart mapping. The company was founded in 2016 and is headquartered in Dongguan, China with an additional office in Shenzhen, China.

Developer of synthetic biotechnology intended to facilitate microbial manufacturing and material innovation. The company focuses on the research and development of synthetic biotechnology and applies synthetic biology to create new bio-manufacturing products and to optimize cells from energy to medicines among other applications, enabling clients to assemble products by bio-engineering cell materials.

Suzhou Ribo Life Science is a developer of RNA interference ( RNAi ) technology designed to treat liver diseases. The company's RNA interference ( RNAi ) technology is used to develop nucleic acid therapeutic drugs and related products, enabling healthcare providers to deliver more effective pharmaceuticals to patients.

Nanjing IASO Biotherapeutics is a clinical-stage biotechnology company established in 2017, specializing in the development of innovative therapies for cancer treatment. The company focuses on creating engineered autologous and allogenic T cell therapies aimed at enhancing the immune system's ability to identify and eliminate cancer cells. Its work centers on the discovery, development, and potential commercialization of cell therapies specifically in the oncology sector, striving to advance cancer care through these advanced therapeutic approaches. Based in Nanjing, China, IASO Biotherapeutics is dedicated to addressing the challenges posed by cancer through its targeted treatment solutions.

Nanovision Technology, based in the Zhongguancun Yongfeng high-tech industrial base with an additional subsidiary in Chengdu, specializes in high-speed and high-precision radiology imaging. The company focuses on the development of static CT, X-ray CMOS detectors, and X-ray imaging software. Notably, Nanovision created China's first self-developed CMOS flat panel detector, known as the Merak series. Its products are applicable in various sectors, including medical, industrial, and security, offering advanced technological support both domestically and internationally. With a significant research and development foundation, Nanovision is positioned as a key player in the radiation imaging industry.

NextCure, Inc. is a clinical-stage biopharmaceutical company based in Beltsville, Maryland, dedicated to discovering and developing innovative immunomedicines for cancer and other immune-related diseases. The company’s lead product candidate, NC318, is currently undergoing Phase 2 clinical trials aimed at treating advanced or metastatic solid tumors. Additionally, NextCure is advancing NC410, an immunomedicine designed to counteract immune suppression through targeting an immune modulator known as Leukocyte-Associated Immunoglobulin-like Receptor 1. The company is also engaged in research programs evaluating novel immunomodulatory molecules, including antibodies in preclinical development that target specific immune modulators in inflamed tissues and tumor microenvironments. NextCure has established a license agreement with Yale University and collaborates with Eli Lilly and Company for research and development efforts. Founded in 2015, the company leverages proprietary platforms to identify biologically relevant targets and develop first-in-class immunotherapy products.

Omniome, Inc. is a biotechnology company based in San Diego, California, established in 2013. It specializes in developing a proprietary DNA sequencing platform that aims to deliver high accuracy in sequencing results. The company employs its Sequencing By Binding technology, which enhances nucleotide and DNA matching by utilizing the natural matching capabilities of polymerase. This innovative approach not only provides precise and rapid results but also offers a cost-effective solution, which has the potential to significantly advance cancer diagnostics. Omniome is backed by prominent life sciences venture investors and is focused on becoming a trusted leader in the field of clinical sequencing.

ThinkForce is a Shanghai-based company specializing in the production of artificial intelligence semiconductors. The firm develops intelligent semiconductors that integrate advanced AI algorithms and hardware platforms, focusing on creating specialist multi-core processors designed for high parallel processing capabilities. These processors consist of numerous simpler, independent cores, allowing clients to utilize chip virtualization services that function as a central processing unit for multiple independent computers. With a strong technical team, ThinkForce is committed to ensuring the successful integration of its technologies into various industrial applications.

Neon Therapeutics is a clinical-stage biopharmaceutical company specializing in neoantigen-targeted therapies aimed at advancing cancer treatment. By focusing on the immune system's response to neoantigens, the company seeks to develop innovative therapies that enhance the body's ability to fight cancer. Its product pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01, which are designed to leverage the unique characteristics of neoantigens to improve patient outcomes.

Nio Limited is a prominent electric vehicle manufacturer based in Shanghai, China, focusing on the premium segment of the market. Founded in 2014, the company designs, jointly manufactures, and sells smart electric vehicles, including five, six, and seven-seater SUVs. Nio is recognized for its innovative technology, including battery swapping and autonomous driving features, which enhance user experience. Its model lineup includes the ES8, a high-performance seven-seater SUV launched in 2018, the ES6 five-seater SUV, and the EC6 electric coupe SUV. The company also provides a range of charging solutions, such as home charging, battery swapping services, and mobile charging options, alongside value-added services like insurance and maintenance. In addition to its electric vehicle offerings, Nio collaborates with organizations like Mobileye N.V. to advance its technology. As of 2023, Nio has sold over 160,000 electric vehicles, capturing approximately 2% of the new energy vehicle market in China.

Nio Limited is a prominent electric vehicle manufacturer based in Shanghai, China, focusing on the premium segment of the market. Founded in 2014, the company designs, jointly manufactures, and sells smart electric vehicles, including five, six, and seven-seater SUVs. Nio is recognized for its innovative technology, including battery swapping and autonomous driving features, which enhance user experience. Its model lineup includes the ES8, a high-performance seven-seater SUV launched in 2018, the ES6 five-seater SUV, and the EC6 electric coupe SUV. The company also provides a range of charging solutions, such as home charging, battery swapping services, and mobile charging options, alongside value-added services like insurance and maintenance. In addition to its electric vehicle offerings, Nio collaborates with organizations like Mobileye N.V. to advance its technology. As of 2023, Nio has sold over 160,000 electric vehicles, capturing approximately 2% of the new energy vehicle market in China.

Nio Limited is a prominent electric vehicle manufacturer based in Shanghai, China, focusing on the premium segment of the market. Founded in 2014, the company designs, jointly manufactures, and sells smart electric vehicles, including five, six, and seven-seater SUVs. Nio is recognized for its innovative technology, including battery swapping and autonomous driving features, which enhance user experience. Its model lineup includes the ES8, a high-performance seven-seater SUV launched in 2018, the ES6 five-seater SUV, and the EC6 electric coupe SUV. The company also provides a range of charging solutions, such as home charging, battery swapping services, and mobile charging options, alongside value-added services like insurance and maintenance. In addition to its electric vehicle offerings, Nio collaborates with organizations like Mobileye N.V. to advance its technology. As of 2023, Nio has sold over 160,000 electric vehicles, capturing approximately 2% of the new energy vehicle market in China.